DARE News and Press, Dare Bioscience Inc. From 01/25/23

The women’s health company Daré Bioscience ( NASDAQ: DARE ) added ~13% on Wednesday to reach the highest level since June 2022 after announcing that its shares have regained Nasdaq compliance for continued listing. According to a Nasdaq communication on Jan. 24, Dar&#x...

Daré Plans to Advance DARE-HRT1 into Single Phase 3 Efficacy Trial for Treatment of Vasomotor Symptoms (VMS) due to Menopause DARE-HRT1 has the potential to be the first FDA-approved monthly intravaginal ring delivering both estrogen and progestogen hormone therapy SAN DIEGO,...

DARE -PDM1 Utilizes Proprietary Hydrogel Technology for Vaginal Delivery of Diclofenac, a Nonsteroidal Anti-Inflammatory; Phase 1 Study Targeted for 2023 2022 Daré Portfolio Accomplishments Include : Two Additional Portfolio Programs (DARE-GML and grant-funded DARE-...

Daré Bioscience ( NASDAQ: DARE ) said it received a grant of ~$585K from the Bill & Melinda Gates Foundation to support development of a vaginal thermosetting gel formulation for delivery of live biotherapeutics which can be reconstituted at the point of care...

Grant Funds Will Support Development of a Reconstitutable Vaginal Thermosetting Gel Formulation to Ultimately Serve as a Delivery Vehicle that Allows Administration of Live Biotherapeutics at the Point of Care in a Wide Range of Settings SAN DIEGO, Nov. 15, 2022 (GLOBE NEWSWIRE) -- ...

DARE-VVA1 Demonstrated Improvement in Vaginal Cytology Parameters and Bothersome Symptoms of Vulvar and Vaginal Atrophy (VVA), Supporting Ongoing Development Investigational Therapy for Women with VVA Who Cannot, or Should Not, Take Supplemental Estrogen, Including Women w...

The following slide deck was published by Daré Bioscience, Inc. in conjunction with their 2022 Q3 earnings call. For further details see: Daré Bioscience, Inc. 2022 Q3 - Results - Earnings Call Presentation

Dare Bioscience, Inc. (DARE) Q3 2022 Earnings Conference Call November 10, 2022, 04:30 PM ET Company Participants Sabrina Johnson - President and Chief Executive Officer Lisa Walters-Hoffert - Chief Financial Officer John Fair - Chief Strategy Officer Confe...

Dare Bioscience press release ( NASDAQ: DARE ): Q3 GAAP EPS of -$0.08 beats by $0.03 . Cash and cash equivalents: $40.4 million at September 30, 2022, compared to $51.7 million at December 31, 2021. During the third quarter, Company received $18.0 million in non-di...

September 30, 2022: $40.4 million in cash and cash equivalents Ovaprene ® : IDE approval from FDA for pivotal Phase 3 study; additional study design considerations being reviewed and implemented to further position the study as the single pivotal study for marketing approval ...